Nanoscaled Discovery of a Shunt Rifamycin from Salinispora arenicola Using a Three-Color GFP-Tagged Staphylococcus aureus Macrophage Infection Assay

ACS Infect Dis. 2023 Aug 11;9(8):1499-1507. doi: 10.1021/acsinfecdis.3c00049. Epub 2023 Jul 11.

Abstract

Antimicrobial resistance has emerged as a global public health threat, and development of novel therapeutics for treating infections caused by multi-drug resistant bacteria is urgent. Staphylococcus aureus is a major human and animal pathogen, responsible for high levels of morbidity and mortality worldwide. The intracellular survival of S. aureus in macrophages contributes to immune evasion, dissemination, and resilience to antibiotic treatment. Here, we present a confocal fluorescence imaging assay for monitoring macrophage infection by green fluorescent protein (GFP)-tagged S. aureus as a front-line tool to identify antibiotic leads. The assay was employed in combination with nanoscaled chemical analyses to facilitate the discovery of a new, active rifamycin analogue. Our findings indicate a promising new approach for the identification of antimicrobial compounds with macrophage intracellular activity. The antibiotic identified here may represent a useful addition to our armory in tackling the silent pandemic of antimicrobial resistance.

Keywords: Salinispora arenicola; Staphylococcus aureus; fluorescence imaging assay; macrophage; rifamycin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Green Fluorescent Proteins / genetics
  • Humans
  • Macrophages
  • Rifamycins* / therapeutic use
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus

Substances

  • Green Fluorescent Proteins
  • Rifamycins
  • Anti-Bacterial Agents

Supplementary concepts

  • Salinispora arenicola